Insiders who reported open-market trades in the last 12 months at the companies Ansbert Gadicke files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
EcoR1 Capital, LLC - $40.00M in AKTS purchases and sales in the last 12 months
Ansbert Gadicke is a corporate insider of Aktis Oncology, Inc. (AKTS). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Ansbert Gadicke last file a Form 4?
The most recent primary Form 4 on record is dated 14 January 2026, one of 12 filings going back to 2025.
Has Ansbert Gadicke been buying or selling stock?
Recorded transactions: 1 open-market purchase ($20.03M) and 30 open-market sales ($10.55M) across all tracked filings.
Ansbert Gadicke files SEC Form 4 reports at Aktis Oncology, Inc. (AKTS). 12 SEC Form 4 filings on record going back to 2025, most recently on 14 January 2026. Most recent open-market trade: bought $20.03M of AKTS on 14 January 2026. Lifetime open-market purchases: $20.03M. Lifetime open-market sales: $10.55M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Ansbert Gadicke.
InsiderAlpha's records for Ansbert Gadicke go back to 2025: 12 primary Form 4 filings, an average of 6.0 per year. The typical open-market purchase is $20.03M (1 buy totaling $20.03M). The largest single buy on record is $20.03M of AKTS in 2026. Sales side: 30 recorded sales totaling $10.55M, so the filing history runs buy-heavy by dollar value. 28 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
